tbuckley/cabot-search huggingface dataset:
The PerSeUS-BC01 study: A phase II study of nab-PTX followed by EC as neoadjuvant chemotherapy in breast cancer patients.
Authors: Manabu Futamura, Yasuko Nagao, Kazuhiro Ishihara, Makoto Takeuchi, Takumi Nakada, Yoshihiro Kawaguchi, Masayoshi Asano, Iwao Kumazawa, Takashi Shiroko, Ryutaro Mori, Kasumi Morimitsu, Masahito Nawa, Harumi Takahashi, Akemi Morikawa, Fumio Sakashita, Chika Takao, Yoshiki Hosono, Yoshimi Asano, Masako Kanematsu, Kazuhiro Yoshida
Journal: Journal of Clinical Oncology (2015)

e12000 Background: A combination of anthracycline and taxane is a standard regimen for neoadjuvant chemotherapy (NAC) in breast cancer. Nab-PTX might have a higher pathological complete response (pCR) rate and lower toxicity. In the present multicenter phase II study, we aimed to investigate the efficacy and toxicity of nab-PTX followed by EC as NAC. Methods: Operable, stage I-IIIB breast cancer patients [Luminal B (Lum): Ki67 ≥ 15% or NG3, HER2+, triple negative (TN)] with measurable disease based on the RECIST, were eligible for the study (UMIN000009035). Fifty-five patients with an ECOG PS ≤ 1, and with adequate bone marrow, and renal and hepatic function were enrolled to receive 4 cycles of nab-PTX (260 mg/m2 q3w) followed by 4 cycles of EC (epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2) q3w. HER2+ patients received additional treatment with trastuzumab (loading dose, 8 mg/kg, followed by 6 mg/kg). The primary endpoint was the pCR rate (ypT0/is ypN0). Secondary endpoints were the overall response rate (ORR), rate of breast conserving surgery (BCS), and toxicity. Results: In total, 55 patients were enrolled (Lum: 21, Lum/HER2+: 14, HER2+: 6, and TNBC: 14). The median age was 52.9 years. Out of the total, 49 patients were evaluable. The pCR rate was 24.5% (12/49) [Lum: 15.0% (3/20), Lum/HER2: 25.0% (3/12), HER2+: 50.0% (3/6), TN: 27.3% (3/11)]. The ORR was 71.4% (35/49), and the rate of BCS was 40.8% (20/49). Toxicity ( ≥ Grade3) included leucopenia (13.0%), neutropenia (50.0%), myalgia or arthralgia (16.7%), peripheral sensory neuropathy (7.4%), hepatobiliary disorder (5.6%), peripheral motor neuropathy, or skin rash (2.0%) during nab-PTX treatment. Moreover, neutropenia (49.0%), leukopenia (38.8%), febrile neutropenia (6.1%), anemia, hepatobiliary disorder, anorexia, peripheral sensory neuropathy, and phlebitis (2.0%) occurred during treatment with EC. Conclusions: Results demonstrate that the pCR rate following the PerSeUS BC01 regimen was similar to that of previous q3w protocols, and that the toxicity was lower. As SPARC may mediate intratumoral accumulation of nab-PTX, the correlation of SPARC expression with clinical response will also be presented at the meeting. Clinical trial information: 000009035.
Abstract 17208: Diagnostic Performance of Novel CT-Fractional Flow Reserve Based on Structural and Fluid Analysis Using 4D-CT Image
Authors: Yuko Kawaguchi, Shinichirou Fujimoto, Kanako Kumamaru, Tomotaka Dohi, Keiken Ri, Kazuhisa Takamura, Etsuro Kato, Yoshiteru Kato, Hiroshi Tamura, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida
Journal: Circulation (2016)

Introduction: Recently, a method to calculate fractional flow reserve (FFR) by applying the principle of computational fluid dynamics based on coronary CT angiography (CCTA), and the its clinical usefulness has been reported. However, as for the diagnostic ability, compared to the sensitivity, especially, its specificity is said to have a variation. Using structural and fluid analysis and taking changes in coronary shape, movement, cross sectional area and cubic volume in multiple cardiac phases into consideration, an algorism of CT-FFR analysis which enables to set boundary conditions which are specific for individual patients has been developed. However, data about its clinical usefulness hardly have been reported. In this study, we evaluated the diagnostic performance of CT-FFR using the new algorism as a reference of invasive FFR. Methods: The subjects were consecutive 22 cases with 26 vessels in which stenosis of 30-90% was detected at one vessel of at least 2mm or more in the major epicardial vessel...
Neuropilin-1 and lung cancer progression: Potential role of targeting neuropilin-1 as an anti-tumor strategy
Authors: Yuh-Ling Chen, Yi-Ying Wu, Yi-Chuan Chung, Yu-Chih Chao, Shuenn-Chen Yang, Jin-Yuan Shih, Ang Yuan, Tse-Ming Hong, Pan-Chyr Yang
Journal: Cancer Research (2006)

1632   Neuropilin-1 (NRP1) is a co-receptor for vascular endothelial growth factor-A (VEGF165) and semaphorins that expressed in endothelial cells and various cancer cells. We previously identified by microarray that NRP1 expression is correlated with the invasive ability in lung cancer cells. This study we investigate the molecular mechanisms of NRP1 signaling in lung cancer progression and potential therapeutic implications. The expressions of NRP1 mRNA in non-small cell lung cancer (NSCLC) tumor specimens were analyzed by real-time quantitative reverse-transcription polymerase chain reaction and correlated with disease-free survivals and overall survivals of the patients. A cyclic 7-mer phage display peptide library was screened for NRP1-binding peptides using soluble NRP1 (sNRP1) as the bait, and examined their binding affinity by surface plasmon resonance. The role of NRP1 in lung cancer cells invasion, angiogenesis and signaling were characterized by either stimulation with VEGF165 or inhibition of NRP1 activities by specific siRNAs, sNRP1 and NRP1-binding peptides. The signaling pathway of NRP1 in lung cancer cells was investigated by Western blotting of several secondary messengers phosphorylation. The expressions of NRP1 mRNA in tumor specimens are negatively correlated with the overall and disease-free survivals in 65 NSCLC patients. The NRP1 signalings induced by VEGF165 in lung cancer cells are involved VEGF receptor 2 (VEGFR2) phosphorylation, activation of phosphoinositide-3 kinase (PI3K) and Akt phosphorylation. The down-regulation of NRP1 by siRNA and sNRP1 suppresses these signalings and leads to the suppression of invasion ability and filopodia formation. Phage display identified small peptides with the consensus sequences of RRXR that had anti-NRP1 activity. Two selected peptides DG1 and DG2 targeting to NRP1 were synthesized that can suppress the NRP1 downstream signaling, invasion ability, filopodia formation and tumor angiogenesis. Our findings indicate that NRP1 plays a crucial role in lung cancer progression. The NRP1 signaling induced by VEGF is mediated through a pathway involving VEGFR2 phosphorylation and activation of PI3K and Akt kinase. The NRP1-binding peptides that can suppress VEGF/NRP1/VEGFR2/PI3K/Akt signaling and cancer cell invasion as well as angiogenesis may have therapeutic potential.
PS-163-Faecal microbiota transplantation with tenofovir is superior to tenofovir alone in improving clinical outcomes in acute-on-chronic liver failure due to hepatitis B: An open label randomized controlled trial (NCT02689245)
Authors: Juned Ahmad, Manoj Kumar, Shiv Kumar Sarin, Shvetank Sharma, Ashok Choudhury, Ankur Jindal, Nirupma Trehanpati, Anand Kulkarni, Shakti Choudhury, Dr. Abhinav Verma
Journal: Journal of Hepatology (2019)
THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance
Authors: Silvia Barbaliscia, Velia Chiara Di Maio, Elisabetta Teti, Marianna Aragri, Stefania Paolucci, Chiara Masetti, Roberta D’ambrosio, Ennio Polilli, Valeria Pace Palitti, Gianluca Fiorentino, Valeria Cento, Rossana Scutari, Bianca Bruzzone, Vincenza Calvaruso, Coppola Nicola, Giovanni Battista Gaeta, Giulia Morsica, Valeria Ghisetti, Ada Bertoli, Martina Milana, Luca Foroghi, Laura Ambra Nicolini, Vanni Borghi, Riccardo Campoli, Silvia Galli, Carlo Federico Magni, Valeria Micheli, Vincenzo Boccaccio, Renato Maserati, Stefano Bonora, Nerio Iapadre, Filomena Morisco, Massimo Siciliano, Pietro Andreone, Miriam Lichtner, Pierpaolo Paba, Loredana Sarmati, Massimo Puoti, Antonio Craxi, Adriano Pellicelli, Sergio Babudieri, Giuliano Rizzardini, Gloria Taliani, Pietro Lampertico, Caterina Pasquazzi, Giustino Parruti, Angelico Mario, Massimo Andreoni, Carlo Federico Perno, Francesca Ceccherini Silberstein
Journal: Journal of Hepatology (2019)
Abstract 15440: Prevalence, Mechanism, and Prognostic Significance of Myeloproliferative Neoplasm-Associated Right Ventricular Dysfunction
Authors: Jiwon Kim, Sara Rodriguez-Diego, Antonino Di Franco, Rupa K Patil, Neil Mehta, Samantha R Goldburg, Jonathan Y Siden, Spencer A Krichevsky, Richard B Devereux, Joseph M Scandura, Evelyn Horn, Jonathan W Weinsaft
Journal: Circulation (2017)

Introduction: Pts with myeloproliferative neoplasms (MPN) are at risk for pulmonary hypertension (PH), which provides a nidus for RV dysfunction (RVDYS). Prevalence, mechanism and prognostic implications of RVDYS in MPN is unknown. Methods: MPN pts undergoing transthoracic echo were studied. RVDYS was defined via standard linear criteria (TAPSE 35mmHg), among whom RVDYS was 5 fold more common (20% vs 4%; p=0.001). RVDYS magnitude increased stepwise in relation to PAP (p<0.001); GLS was 1.5 fold lower (15.6±3.8 vs 23.3±3.6; p<0.001) among pts in the top vs bottom PAP stratum. Pts...
Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients
Authors: B. Gutiérrez-Gutiérrez, J. Rodríguez-Baño
Journal: Clinical Microbiology and Infection (2019)

BackgroundExtended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used drugs to treat these infections. However, due to the increasing rates of resistance to these antimicrobials, carbapenem-sparing alternatives are being investigated.Objectives and sourcesThe aim of this narrative literature review is to summarize the published information on the currently available antibiotics for the treatment of ESBL-E infections, providing specific information on three subgroups of patients: Group 1, patients with severe infections or infections from high-risk sources or in severely immunocompromised patients; Group 2, patients with non-severe infections from intermediate-risk source; and Group 3, patients with non-severe urinary tract infection.Content and implicationsFor patients in Group 1, the current data would support the use of carbapenems. For milder infections, however, particularly urinary tract infections, other non-carbapenem antibiotics can be considered in selected cases, including beta-lactam/beta-lactam inhibitor combinations, cephamycins, temocillin and aminoglycosides. While specific studies should be performed in these situations, individualized decisions may be taken in order to avoid overuse of carbapenems.
The Search for an Effective Therapy and Pain Relief for Oral Mucositis
Authors: Sharon Elad, Noam Yarom
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study
Authors: U. Weinberg, O. Farber, M. Giladi, Z. Bomzon, E. Kirson
Journal: Annals of Oncology (2019)

Background: Tumor Treating Fields (TTFields), a non-invasive anti-mitotic treatment, added to temozolomide significantly extended survival in newly diagnosed glioblastoma. TTFields is eficacious in preclinical in vitro and in vivo NSCLC models. A phase I/II study [NCT00749346] of advanced NSCLC of TTFields plus pemetrexed detected no serious adverse events; median overall survival (OS) of 13.8 months. The Phase 3 LUNAR study [NCT02973789] investigates if TTFields added to immune checkpoint inhibitors or docetaxel following platinum failure will increase overall survival (OS). Trial design: Patients (n = 534) with squamous or non-squamous NSCLC, are stratified by therapy (immune checkpoint inhibitors or docetaxel), histology (squamous vs. non-squamous) and geographical region. Key inclusion criteria: disease progression on or after platinum-based therapy, ECOG 0-2, no electronic medical devices in upper torso, and absence of brain metastases. Docetaxel or immune checkpoint inhibitors are given at standard doses. TTFields (150 kHz) are applied to the upper torso for >18 hours/day. TTFields are continued until progression in the thorax and/or liver. Follow up is performed once q6 weeks, including CT scans of the chest and abdomen. On progression in the thorax and/or liver, patients have 3 post-progression follow up visits and are then followed monthly for survival. The primary endpoint is superiority in OS between patients treated with TTFields in combination with the standard of care treatments versus standard of care treatments alone. Key secondary endpoints compare the OS in patients treated with TTFields and docetaxel versus docetaxel alone, and patients treated with TTFields and immune checkpoint inhibitors vs those treated with immune checkpoint inhibitors alone. An exploratory analysis will test non-inferiority of TTFields with docetaxel compared to checkpoint inhibitors alone. Secondary endpoints include progression-free survival, radiological response rate, quality of life based on the EORTC QLQ C30 questionnaire and severity and frequency of adverse events. The sample size is powered to detect a HR of 0.75 in TTFields-treated patients versus control group. Clinical trial identification: NCT02973789. Legal entity responsible for the study: Novocure. Funding: Novocure. Disclosure: U. Weinberg, O. Farber, M. Giladi, Z. Bomzon, E. Kirson: Full time employee, stock options: Novocure.
THU-093-The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of non-alcoholic steatohepatitis
Authors: Mozhdeh Sojoodi, Smitha Krishnan, Allen A. Razavi, Michael R. Day, Gunisha Arora, Sarani Goshal, Shen Li, Derek J. Erstad, Peter Caravan, Kenneth K. Tanabe, Maria E. Fuentes, Bryan C. Fuchs
Journal: Journal of Hepatology (2019)
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
Authors: Vincent Sobanski, Jonathan Giovannelli, Yannick Allanore, Gabriela Riemekasten, Paolo Airò, Serena Vettori, Franco Cozzi, Oliver Distler, Marco Matucci‐Cerinic, Christopher Denton, David Launay, Eric Hachulla
Journal: Arthritis & Rheumatology (2019)

Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis.
Triple therapy in COPD: only for the right patient
Authors: Samy Suissa, Amnon Ariel
Journal: European Respiratory Journal (2019)

<b>The TRIBUTE and IMPACT trials comparing triple therapy with LAMA/LABA in COPD have methodological limitations that inherently favor triple therapy; use with caution by targeting the right drug for the right patient in terms of both benefit and risk</b>http://ow.ly/Bbsr30nXffO
MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis
Authors: Kulveer Mankia, Maria-Antonietta D'Agostino, Emma Rowbotham, Elizabeth MA Hensor, Laura Hunt, Ingrid Möller, Misabel Miguel, José Ramon Mérida-Velasco, Jorge Murillo-González, Esperanza Naredo, Jacqueline Leong Nam, Ai Lyn Tan, Jane E Freeston, Andrew Grainger, Paul Emery
Journal: Annals of the Rheumatic Diseases (2019)

Interosseous tendon inflammation (ITI) has been described in rheumatoid arthritis (RA). Whether ITI occurs in at-risk individuals before the onset of clinical synovitis is unknown. Objectives To investigate, by MRI, ITI in anti-cyclic citrullinated peptide (CCP)-positive at-risk individuals (CCP +at risk) and to describe the anatomy, prevalence and clinical associations across the RA continuum. Methods Hand MRI was performed in 93 CCP + at risk, 47 early RA (ERA), 28 established ‘late’ RA (LRA) and 20 healthy controls (HC) and scored for ITI, flexor tenosynovitis (TSV) and RA MRI scoring at the metacarpophalangeal joints (MCPJs). Cadaveric and histological studies were performed to explore the anatomical basis for MRI ITI. Results The proportion of subjects with ITI and the number of inflamed interosseous tendons (ITs) increased along the disease continuum (p&lt;0.001): 19% of CCP +at risk, 49% of ERA and 57% of LRA had ≥1 IT inflamed . ITI was not found in any HC. ITI was more frequently identified in tender MCPJs compared with nontender MCPJs (28% vs 12%, respectively). No IT tenosynovial sheath was identified in cadavers on dissection or histological studies suggesting MRI findings represent peritendonitis. Dye studies indicated no communication between the IT and the joint. Conclusions ITI occurs in CCP + at-risk individuals and can precede the onset of clinical synovitis. The ITs may be important nonsynovial extracapsular targets in the development and progression of RA.
FRI-467-Optimal time-point of response assessment was associated with tumour burden in patients with unresectable hepatocellular carcinoma undergoing repeated transarterial chemoembolization
Authors: Dongdong Xia, Enxin Wang, Qiuhe Wang, Wei Bai, Zhexuan Wang, Wei Mu, Junhui Sun, Ming Huang, Guowen Yin, Hailiang Li, Hui Zhao, Chunqing Zhang, Jing Li, Jianbing Wu, Xiaoli Zhu, Shufa Yang, Xingnan Pan, Jiaping Li, Zixiang Li, Guohui Xu, Haibin Shi, Wenjun Wang, Jing Niu, Jie Yuan, Xiaomei Li, Yong Lv, Kai Li, Zhanxin Yin, Daiming Fan, Jielai Xia, Guohong Han
Journal: Journal of Hepatology (2019)
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC
Authors: G. Mazzaschi, F. Quaini, G. Milanese, D. Madeddu, G. Bocchialini, L. Ampollini, L. Gnetti, C. Lagrasta, M. Silva, G. Roti, N. Sverzellati, M. Tiseo
Journal: Annals of Oncology (2019)

Background: The ground-breaking advent of immunotherapy in the oncologic arena still leaves uncovered the identification of valid prognostic and predictive biomarkers. To this aim, we advanced the hypothesis that intersecting the tumor immune microenvironment (TIME) with high-throughput extracted radiomic features may identify NSCLC patients with distinct clinical outcome. Methods: We enrolled 60 surgically resected NSCLC patients. TIME was assessed by the quantitative evaluation of PD-L1 levels and an extensive morphometric analysis of Tumor Infiltrating Lymphocytes (TILs). From each CT scan, in addition to semantic characteristics, 841 radiomic features were extracted through an open-source (3d Slicer) software. Radiomic variables were subjected to statistical analysis to test their correlation with tissue immune profiles and survival outcome. Results: A cluster of 3 patients (A) displaying oppositely regulated radiomic features was identified by an unsupervised hierarchical model. Compared to the remaining cases, cluster A had a significantly reduced (p < 0.01) OS (13 vs 33 mos.) and DFS (11 vs 25 mos.) and shared similar semantic imaging characteristics (no effect on parenchyma and subsolid texture) and a desertic TIME (PD-L1low and TILslow). Radiomic variables from cluster A were then compared to those extracted from patients matched for both desertic TIME and qualitative CT parameters but with favorable survival outcome (cluster B). By applying signal-to-noise ratio and T-test, the most significant oppositely regulated wavelet features (p < 0.0001) in the two clusters were Large Dependence Emphasis, Busyness, Cluster-Tendency and Gray Level Variance. The detailed analysis of corresponding TIME revealed that PD-1-to-CD8 ratio was the only immunophenotypic parameter differentially expressed by the two prognostic classes. Conclusions: Higher order radiomic features associated with specific TILs phenotype may enclose a radiologic signature with prognostic impact on NSCLC. Legal entity responsible for the study: University Hospital of Parma. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Annals Story Slam - Doing This for 20 Years
Authors: Horace M. DeLisser
Journal: Annals of Internal Medicine (2019)

Web Exclusives7 May 2019Annals Story Slam - Doing This for 20 YearsFREEHorace M. DeLisser, MDHorace M. DeLisser, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0003 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Doing This for 20 Years "Doing This for 20 Years," by Dr. Horace M. DeLisser (Duration 6:58)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: This article was published at Annals.org on 12 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 May 2019Volume 170, Issue 9Page: SS1 ePublished: 12 April 2019 Issue Published: 7 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...